Boston gets US nod for Liberte stent, firm pits DES vs bypass
This article was originally published in Clinica
Executive Summary
The US FDA has given Boston Scientific the all-clear to sell its new bare metal coronary stent, Liberte, which will also serve as the platform for the firm's next-generation paclitaxel-eluting stent, Taxus Liberte. The company has also begun what it calls a groundbreaking trial to compare drug-eluting stents (DESs) with heart bypass surgery in patients with the severest form of coronary artery disease.